Inbrija is a drug owned by Merz Pharmaceuticals Llc A Sub Of Merz Therapeutics Gmbh. It is protected by 18 US drug patents filed in 2019. Out of these, 5 drug patents are active and 13 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 16, 2032. Details of Inbrija's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9393210 | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | Active |
| US8685442 | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | Active |
| US8945612 | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | Active |
| US8545878 | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | Active |
| USRE43711 | Pulmonary delivery for levodopa |
Feb, 2029
(4 years from now) | Active |
| US7182961 | Particulate compositions for pulmonary delivery |
Feb, 2024
(8 months ago) |
Expired
|
| US9155699 | Pulmonary delivery for levodopa |
Mar, 2023
(1 year, 7 months ago) |
Expired
|
| US8586093 | Pulmonary delivery for levodopa |
Mar, 2023
(1 year, 7 months ago) |
Expired
|
| US8404276 | Pulmonary delivery for levodopa |
Mar, 2023
(1 year, 7 months ago) |
Expired
|
| US7384649 | Particulate compositions for pulmonary delivery |
Nov, 2022
(1 year, 11 months ago) |
Expired
|
| US6858199 | High efficient delivery of a large therapeutic mass aerosol |
Nov, 2021
(2 years ago) |
Expired
|
| US7556798 | Highly efficient delivery of a large therapeutic mass aerosol |
Nov, 2021
(2 years ago) |
Expired
|
| US7146978 | Inhalation device and method |
Apr, 2021
(3 years ago) |
Expired
|
| US6514482 | Pulmonary delivery in treating disorders of the central nervous system |
Sep, 2020
(4 years ago) |
Expired
|
| US6613308 | Pulmonary delivery in treating disorders of the central nervous system |
Sep, 2020
(4 years ago) |
Expired
|
| US6979437 | Pulmonary delivery in treating disorders of the central nervous system |
Sep, 2020
(4 years ago) |
Expired
|
| US6921528 | Highly efficient delivery of a large therapeutic mass aerosol |
Jun, 2020
(4 years ago) |
Expired
|
| US8628754 | Highly efficient delivery of a large therapeutic mass aerosol |
Jun, 2020
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Inbrija's patents.
Latest Legal Activities on Inbrija's Patents
Given below is the list of recent legal activities going on the following patents of Inbrija.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jan, 2024 | US9393210 |
| Expire Patent Critical | 20 Nov, 2023 | US9155699 |
| Maintenance Fee Reminder Mailed Critical | 05 Jun, 2023 | US9155699 |
| Expire Patent Critical | 21 Feb, 2022 | US8628754 |
| Maintenance Fee Reminder Mailed Critical | 06 Sep, 2021 | US8628754 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 May, 2021 | US8586093 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 17 Mar, 2021 | US8545878 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Dec, 2020 | US7556798 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Sep, 2020 | US8404276 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Jan, 2020 | US9393210 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Inbrija and ongoing litigations to help you estimate the early arrival of Inbrija generic.
Inbrija's Litigations
Inbrija been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 27, 2004, against patent number US7556798. The petitioner , challenged the validity of this patent, with David A. Edwards et al as the respondent. Click below to track the latest information on how companies are challenging Inbrija's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7556798 | May, 2007 |
Decision
(18 Aug, 2008) | David A. Edwards et al | |
| US7556798 | August, 2004 |
Decision
(18 Mar, 2005) | David A. Edwards et al | |
FDA has granted some exclusivities to Inbrija. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Inbrija, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Inbrija.
Exclusivity Information
Inbrija holds 1 exclusivities. All of its exclusivities have expired in 2021. Details of Inbrija's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 21, 2021 |
US patents provide insights into the exclusivity only within the United States, but Inbrija is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Inbrija's family patents as well as insights into ongoing legal events on those patents.
Inbrija's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Inbrija's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 16, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Inbrija Generics:
There are no approved generic versions for Inbrija as of now.
Alternative Brands for Inbrija
Inbrija which is used for managing off episodes in Parkinson's disease patients treated with carbidopa/levodopa through the inhalation of levodopa powder particles., has several other brand drugs using the same active ingredient (Levodopa). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||||||
|---|---|---|---|---|---|---|---|
| Avion Pharms |
| ||||||
| Impax |
| ||||||
| Orion Pharma |
|
About Inbrija
Inbrija is a drug owned by Merz Pharmaceuticals Llc A Sub Of Merz Therapeutics Gmbh. It is used for managing off episodes in Parkinson's disease patients treated with carbidopa/levodopa through the inhalation of levodopa powder particles. Inbrija uses Levodopa as an active ingredient. Inbrija was launched by Merz Pharms in 2018.
Approval Date:
Inbrija was approved by FDA for market use on 21 December, 2018.
Active Ingredient:
Inbrija uses Levodopa as the active ingredient. Check out other Drugs and Companies using Levodopa ingredient
Treatment:
Inbrija is used for managing off episodes in Parkinson's disease patients treated with carbidopa/levodopa through the inhalation of levodopa powder particles.
Dosage:
Inbrija is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 42MG | POWDER | Prescription | INHALATION |